Welcome to our dedicated page for BIODESIX SEC filings (Ticker: BDSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Want the quick path to Biodesix’s most revealing disclosures? Investors tracking blood-based diagnostic innovators like Biodesix (BDSX) often need to pinpoint reimbursement updates, R&D spend on new lung biomarkers, or insider stock moves before clinical data drops. This SEC filings hub answers those questions in one place.
Navigate straight to the document you need—whether it’s the BDSX quarterly earnings report 10-Q filing that details Nodify Lung revenue, the BDSX annual report 10-K simplified for risk factors around FDA laboratory-developed tests, or the BDSX proxy statement executive compensation that links pay to diagnostic pipeline milestones. Stock Titan’s AI reads every page, producing concise summaries so you can scan complex tables in seconds. That means BDSX SEC filings explained simply, without losing critical nuance.
Real-time alerts flag BDSX Form 4 insider transactions, letting you monitor executive stock activity the moment it hits EDGAR. Need context? Our platform connects each trade to material disclosures so you understand motive, not just movement. You’ll also find:
- BDSX 8-K material events explained for coverage-decision news or new assay launches
- BDSX earnings report filing analysis that compares quarter-over-quarter margin shifts
- BDSX executive stock transactions Form 4 with historical trend charts
From understanding BDSX SEC documents with AI to drilling into BDSX insider trading Form 4 transactions in real time, this page keeps equity analysts, healthcare investors, and strategic partners informed—without wading through hundreds of pages.
John Patience, a director of Biodesix, Inc. (BDSX), reported receipt of 1,144 restricted stock units (RSUs) effective 09/30/2025. The filing notes a one-for-twenty reverse stock split effective 09/15/2025 and states the reported share figures have been adjusted for that split. The RSUs represent contingent rights to receive one share each and vest in three substantially equal installments on 06/30/2025, 09/30/2025, and 12/31/2025, generally subject to continued service, and have no expiration date. The report discloses indirect holdings through Patience Enterprises LP (107,664 shares), the John Patience Living Trust dated 7/23/1993 (241,480 shares), and holdings attributed to a spouse (2,649 shares). The Form is signed by Robin H. Cowie as attorney-in-fact for John Patience on 10/02/2025.
Amendment No. 9 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 2,151,480 shares of Biodesix, Inc., representing approximately 27.0% of the outstanding common stock on a post-reverse-split basis. The filing notes a one-for-twenty reverse stock split effective September 15, 2025, and discloses recent open-market purchases by Mr. Schuler through the Jack W. Schuler Living Trust: 15,317 shares at a weighted average of $6.0437, 3,056 shares at a weighted average of $6.1695, and 142,045 shares purchased in an at-the-market offering at $7.04 per share for an aggregate of $999,996.80. The source of funds for these purchases was Mr. Schuler's personal funds. Beneficial ownership includes options and vested RSUs exercisable/settling within 60 days totaling 20,735 shares; 1,380,745 shares are held by the Trust and 750,000 by a GRAT, with voting and dispositive powers shared accordingly.
Jack W. Schuler, a director and greater-than-10% owner of Biodesix, purchased 142,045 shares of Biodesix Inc. (BDSX) on 09/19/2025 at a price of $7.04 per share. After the purchase, Mr. Schuler beneficially owns 1,380,745 shares indirectly through the Jack W. Schuler Living Trust and holds an additional 750,000 shares indirectly via the Jack W. Schuler 2025 GRAT. The Form 4 was signed by an attorney-in-fact on 09/23/2025. The filing shows no derivative transactions and indicates Mr. Schuler is sole trustee of both the Living Trust and the 2025 GRAT.
Jack W. Schuler, a director and greater-than-10% holder of Biodesix, reported purchases of the issuer's common stock in two transactions. He acquired 15,317 shares at a weighted average price of $6.0437 and 3,056 shares at a weighted average price of $6.1695, increasing reported beneficial ownership to 1,238,700 shares when combining holdings attributed to the Jack W. Schuler Living Trust and other indirect vehicles.
The filing states these amounts were adjusted for a one-for-twenty reverse stock split and discloses an additional 750,000 shares held indirectly in the Jack W. Schuler 2025 GRAT. The transaction footnotes note purchases occurred at varying prices within disclosed ranges; the reporting was signed by an attorney-in-fact.
Biodesix, Inc. (BDSX) completed a one-for-twenty reverse stock split of its common stock effective at 12:01 a.m. ET on September 15, 2025, and began trading on a split-adjusted basis under a new CUSIP (09075X207). The reverse split was authorized by stockholders at the May 20, 2025 annual meeting permitting a split ratio between 1:2 and 1:20; the Board selected the 1-for-20 ratio on September 4, 2025 and filed the required amendment with the Delaware Secretary of State.
Separately, Biodesix filed a Certificate of Elimination with the Delaware Secretary of State effective September 12, 2025 removing the provisions of the Certificate of Designations for the previously issued Series A Non-Voting Convertible Preferred Stock. The filings referenced include a Certificate of Amendment to the charter and the Certificate of Elimination; the document is signed by the CFO and includes embedded Inline XBRL cover page data.
Amendment No. 8 to a Schedule 13D reports that Jack W. Schuler and related entities now beneficially own 39,821,357 shares of Biodesix, Inc., representing approximately 26.0% of the outstanding common stock on a 152,721,438-share base. The filing shows Mr. Schuler holds or has rights to acquire 414,811 shares exercisable within 60 days, 83,152 option shares, and 331,659 settled RSUs exercisable or vesting within 60 days. The filing discloses a purchase on August 29, 2025 by the Trust of 3,488,372 shares at $0.43 per share for an aggregate $1,499,999.96 funded from Mr. Schuler's personal funds. Holdings include 24,406,546 shares in the Jack W. Schuler Living Trust and 15,000,000 shares in the Jack W. Schuler 2025 GRAT. The amendment states no other transactions in the past 60 days.
Insider purchase reported: Jack W. Schuler, a director and more-than-10% owner of Biodesix, Inc. (BDSX), acquired 3,488,372 shares of Biodesix common stock on 08/29/2025 at a reported price of $0.43 per share. After the purchase, Mr. Schuler is shown as beneficially owning 24,406,546 shares indirectly through the Jack W. Schuler Living Trust and an additional 15,000,000 shares indirectly through the Jack W. Schuler 2025 GRAT. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Schuler on 09/03/2025. The filing discloses Mr. Schuler serves as sole trustee for both the Living Trust and the 2025 GRAT.
Robin Harper Cowie, Biodesix (BDSX) officer reported the vesting of 3,157 restricted stock units (RSUs on 08/12/2025) representing rights to 3,157 shares, which increased the reporting persons beneficial ownership to 251,782 shares. The following day (08/13/2025) 988 shares were sold at a weighted average price of $0.4163 to cover taxes arising from the vesting, leaving 250,794 shares beneficially owned. The filing shows the reporting person holds 6,313 RSUs in total that vest in 16 quarterly installments beginning February 8, 2022 and have no expiration date.
This transaction is a routine equity compensation settlement and tax withholding sale rather than an open-market disposition for liquidity; the reporting person remains a significant shareholder and continues to hold vested shares and unvested RSUs.
FAQ
What is the current stock price of BIODESIX (BDSX)?
What is the market cap of BIODESIX (BDSX)?
